How Many Five Prime Therapeutics, Inc. (NASDAQ:FPRX)’s Analysts Are Bullish?

January 11, 2018 - By Adrian Erickson

 How Many Five Prime Therapeutics, Inc. (NASDAQ:FPRX)'s Analysts Are Bullish?
Investors sentiment increased to 1.04 in Q3 2017. Its up 0.34, from 0.7 in 2017Q2. It is positive, as 14 investors sold Five Prime Therapeutics, Inc. shares while 34 reduced holdings. 18 funds opened positions while 32 raised stakes. 23.96 million shares or 0.77% more from 23.78 million shares in 2017Q2 were reported.
Quantbot Tech L P owns 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 220 shares. Lord Abbett And Llc has invested 0.01% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Great West Life Assurance Com Can reported 2,346 shares stake. Fifth Third Bankshares holds 0% or 300 shares in its portfolio. Wells Fargo Co Mn, California-based fund reported 185,382 shares. 34,672 are held by Rhumbline Advisers. Barclays Plc reported 0% stake. Weiss Multi has 15,000 shares. 4.34M are held by Fmr Limited Company. 32,765 were accumulated by Williams Jones Lc. National Bank Of Montreal Can owns 248 shares. 16 are owned by Sei Invests Commerce. Jpmorgan Chase has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Tiaa Cref Investment Mgmt Limited Liability Company holds 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 74,134 shares. Trillium Asset Mgmt Ltd Liability Com holds 64,896 shares.

Since September 28, 2017, it had 0 insider buys, and 2 selling transactions for $148,468 activity.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Ratings Coverage

Among 10 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Five Prime Therapeutics had 21 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Monday, September 11. BMO Capital Markets maintained the stock with “Outperform” rating in Tuesday, November 7 report. The firm earned “Sell” rating on Friday, August 21 by Zacks. The rating was maintained by BMO Capital Markets on Monday, June 5 with “Hold”. The stock has “Outperform” rating by BMO Capital Markets on Monday, October 16. The firm earned “Buy” rating on Tuesday, October 25 by Citigroup. BMO Capital Markets initiated Five Prime Therapeutics, Inc. (NASDAQ:FPRX) rating on Tuesday, April 12. BMO Capital Markets has “Market Perform” rating and $50 target. Credit Suisse maintained it with “Outperform” rating and $52 target in Friday, March 11 report. The rating was upgraded by Zacks on Tuesday, August 11 to “Sell”. Oppenheimer maintained Five Prime Therapeutics, Inc. (NASDAQ:FPRX) rating on Monday, October 19. Oppenheimer has “Outperform” rating and $48 target. Below is a list of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) latest ratings and price target changes.

07/11/2017 Broker: Leerink Swann Rating: Buy
07/11/2017 Broker: Nomura Rating: Buy
07/11/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $71 New Target: $75 Maintain
06/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $50.0 Maintain
16/10/2017 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Outperform Upgrade
20/09/2017 Broker: BMO Capital Markets Rating: Hold New Target: $39.0 Maintain
15/09/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $41 Initiates Coverage On
11/09/2017 Broker: Jefferies Rating: Buy New Target: $52.0 Maintain

The stock decreased 0.95% or $0.21 during the last trading session, reaching $21.92. About 122,718 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 30.56% since January 11, 2017 and is downtrending. It has underperformed by 47.26% the S&P500.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $634.15 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

More notable recent Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news were published by: Streetinsider.com which released: “Five Prime Therapeutics (FPRX) Submits Investigational NDA for Novel B7-H4 …” on January 03, 2018, also Globenewswire.com with their article: “Five Prime Therapeutics to Present at BMO Capital Markets Prescriptions for …” published on December 04, 2017, Globenewswire.com published: “Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO …” on October 23, 2017. More interesting news about Five Prime Therapeutics, Inc. (NASDAQ:FPRX) were released by: Globenewswire.com and their article: “Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3 …” published on January 02, 2018 as well as Streetinsider.com‘s news article titled: “Five Prime Therapeutics (FPRX) Secures $5M IND Milestone Payment from Bristol …” with publication date: January 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.